The Oral GLP-1 Tracker: Novo's Wegovy pill struggles to break through market share ceiling
Fierce Pharma’s Oral GLP-1 Tracker cites IQVIA data and Citi/Jefferies notes on Novo Nordisk’s oral Wegovy pill and Eli Lilly’s oral Foundayo. Wegovy pill oral semaglutide share slipped to 33% from 35%, with ~163K scripts. Total Wegovy scripts fell to ~495.5K. Foundayo scripts rose to 38,928 and Q2 sales were $98M ($67M U.S.).
How this was made
The 30-second read
Why it matters
The newest update highlights sequential script and share changes: Wegovy oral semaglutide share slipping to 33% and Foundayo scripts continuing to rise, while Lilly’s reported Q2 sales of $98M disappointed despite an “inflection point” comment.
Market read
Traders can use the tracker’s sequential script and share movements, plus the reported Q2 sales figure, to gauge near-term momentum and script-to-sales conversion risk for oral GLP-1 leaders.
What to watch
Telehealth data capture uncertainty (IQVIA) could distort script trends; also, Medicare GLP-1 Bridge and DTC marketing timing may shift conversion from scripts to revenue with a lag.
Background
Fierce Pharma’s Oral GLP-1 Tracker uses analyst notes and IQVIA prescription data to monitor oral GLP-1 launches, focusing on Novo’s Wegovy pill and Lilly’s Foundayo.
Ticker impact
Article says Wegovy pill oral semaglutide share fell to 33% last week and total Wegovy scripts slipped to about 495.5K, citing IQVIA/Citi.
Near-term downside bias for NVO versus peers if the “market share ceiling” narrative persists into upcoming earnings.
The piece provides sequential script and share changes (33% oral semaglutide share, scripts down week-over-week) but does not include a new regulatory/clinical outcome or fresh guidance.
Article reports Foundayo scripts rose to 38,928 and notes Q2 sales of $98M (U.S. $67M) disappointed, alongside Medicare GLP-1 Bridge and DTC marketing.
Volatility risk for LLY around interpretation of script-to-sales conversion and telehealth capture, with potential upside if inflection point holds.
The article includes concrete script growth and a specific sales figure, but it is framed as tracker updates and does not provide new earnings guidance beyond the cited CEO commentary.
Market effects
Reinforces competitive pressure in oral GLP-1 adoption, with potential read-through to pricing, channel strategy, and script-to-sales conversion expectations across obesity drugs.
U.S.-centric details (U.S. sales $67M, Medicare GLP-1 Bridge) suggest near-term U.S. channel dynamics are key to the competitive narrative.
Oral GLP-1 competition is likely to influence global obesity-treatment market share expectations, though the article’s data is primarily U.S. and tracker-based.
Counterpoint
Wegovy’s oral share “ceiling” may reflect measurement mix within the franchise, while Foundayo’s script growth could be undercounted or delayed in sales recognition.
Key entities
- companyNovo Nordisk
Subject of the article via Wegovy pill oral GLP-1 tracker results and franchise share changes.
- companyEli Lilly
Subject of the article via Foundayo script growth and Q2 sales disappointment plus channel/coverage initiatives.
- data_providerIQVIA
Cited as the source of prescription trends used in the tracker updates.
- analyst_firmCiti
Cited for interpretation of IQVIA data and market share calculations.
